Me-Too's Struggle
Contrary to common belief, the development of follow-on drugs, often referred to as me-too drugs, does not begin after a first new drug in a therapeutic category receives market approval. The reality is that sponsors are engaged in drug development races that are intensely competitive where the first drug candidate to receive marketing approval belongs to the sponsor that got to the finish line with a satisfactory submission the fastest.
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
- How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
September 11th 2025
- How Recent Policy Changes Could Impact Clinical Research
September 10th 2025